Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin
Preprint
Abstract
Acinetobacter baumannii causes life-threatening infections that are becoming difficult to treat due to increasing rates of multi-drug resistance (MDR) among clinical isolates. This has led the World Health Organization and the CDC to categorize MDR A. baumannii as a top priority for the research and development of new antibiotics. Colistin is the last-resort antibiotic to treat carbapenem-resistant A. baumannii . Not surprisingly, reintroduction of colistin has resulted in the emergence of colistin-resistant strains. Diclofenac is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation associated with arthritis. In this work, we show that diclofenac sensitizes colistin-resistant A. baumannii clinical strains to colistin, in vitro and in a murine model of pneumonia. Diclofenac also reduced the colistin MIC of Klebsiella pneumoniae and Pseudomonas aeruginosa isolates. Transcriptomic and proteomic analyses revealed an upregulation of oxidative stress-related genes and downregulation of type IV pili induced by the combination treatment. Notably, the concentrations of colistin and diclofenac effective in the murine model were substantially lower than those determined in vitro , implying a stronger synergistic effect in vivo compared to in vitro . A pilA mutant strain, lacking the primary component of the type IV pili, became sensitive to colistin in the absence of diclofenac. This suggest that the downregulation of type IV pili is key for the synergistic activity of these drugs in vivo and indicates that colistin and diclofenac exert an anti-virulence effect. Together, these results suggest that the diclofenac can be repurposed with colistin to treat MDR A. baumannii .Keywords
This publication has 90 references indexed in Scilit:
- Modulating Isoprenoid Biosynthesis Increases Lipooligosaccharides and Restores Acinetobacter baumannii Resistance to Host and Antibiotic StressCell Reports, 2020
- Assessing Acinetobacter baumannii Virulence and Persistence in a Murine Model of Lung Infection2019
- Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumanniiJournal of Microbiology, 2017
- Single‐Dose and Multiple‐Dose Pharmacokinetics and Dose Proportionality of Intravenous and Intramuscular HPβCD‐Diclofenac (Dyloject) Compared with Other Diclofenac FormulationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma modelInternational Journal of Cancer, 2012
- Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactionsHepatology, 1995
- Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac*1, *2Hepatology, 1995
- The role of toxin-coregulated pili in the pathogenesis of Vibrio cholerae O1 El TorMicrobial Pathogenesis, 1993
- Toxicity of diclofenac to isolated hepatocytesJournal of Hepatology, 1992